13
Jun
2019

Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Antibody Engineering & Company Building: Bassil Dahiyat on The Long Run
Physician-Scientist-Biotech VC: Vineeta Agarwala on The Long Run
Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run
T Cell Therapies for Autoimmunity: Jeff Bluestone on The Long Run